Posted by Michael Wonder on 06 Feb 2024
Ultragenyx receives PRIME designation from EMA for GTX-102 for the treatment of Angelman syndrome
5 February 2024 - GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation.
Ultragenyx today announced that the EMA has granted Priority Medicine (PRIME) designation to GTX-102 for the treatment of Angelman syndrome.
